PMID- 11172899
OWN - NLM
STAT- MEDLINE
DCOM- 20010322
LR  - 20191210
IS  - 0165-4608 (Print)
IS  - 0165-4608 (Linking)
VI  - 124
IP  - 2
DP  - 2001 Jan 15
TI  - Comparison of the malignant phenotype and genotype of the human 
      androgen-independent cell line DU 145 and a subline derived from metastasis after 
      orthotopic implantation in nude mice.
PG  - 98-104
AB  - To investigate the potential genetic changes underlying the progression of human 
      hormone-resistant prostate cancer, we related chromosomal alterations of the DU 
      145 cell line and a subline isolated form a metastasis in an orthotopic model to 
      tumorigenicity, metastasis and chemoresistance. In 15 mice 1 x 10(5) DU 145 cells 
      were injected into the dorsal prostate. From a resulting paraaortic lymphnode 
      metastasis, we isolated a subline (DU 145 MN1), which was injected into 15 nude 
      mice. The sulforhodamine B (SRB) assay was used to analyze cell doubling time and 
      the IC(50) of cisplatin and 5-fluorouracil for both cell lines. Cytogenetic 
      characterization was performed with conventional karyotype analysis and 
      fluorescence in situ hybridization (FISH). After orthotopic implantation of DU 
      145 cells tumorigenicity was 100% whereas only 2 mice revealed lymphnode 
      metastases. In contrast, the take rate after implantation of DU 145 MN1 was 100%, 
      with lymphnode metastases in 7 mice. The SRB assay revealed a 8-fold increased 
      IC(50) for cisplatin and a 2.5-fold increase for 5-FU in DU 145 MN1 as compared 
      to DU 145 cells. There was gain of a chromosome 8 and only two copies of 
      chromosome 17 in the DU 145 MN1 cells as compared to the parental cell line. The 
      emergence of an i(9)(q10) in addition to two normal chromosome 9 homologues in 
      the DU 145 MN1 cell line was confirmed by FISH using a chromosome 9-specific 
      painting probe. In summary, clonal evolution of the chromosomal changes following 
      repeated orthotopic implantation, may assist in locating the genes involved in 
      the progression and chemoresistance of human hormone-resistant prostate cancer.
FAU - Bex, A
AU  - Bex A
AD  - Clinic of Urology, University of Essen Medical School, 45122 Essen, Germany.
FAU - Wullich, B
AU  - Wullich B
FAU - Endris, V
AU  - Endris V
FAU - Otto, T
AU  - Otto T
FAU - Rembrink, K
AU  - Rembrink K
FAU - Stockle, M
AU  - Stockle M
FAU - Rubben, H
AU  - Rubben H
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Cancer Genet Cytogenet
JT  - Cancer genetics and cytogenetics
JID - 7909240
RN  - 0 (Androgens)
RN  - 0 (Antineoplastic Agents)
RN  - Q20Q21Q62J (Cisplatin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Androgens/*metabolism
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Brain Neoplasms/*genetics/pathology/*secondary
MH  - Cell Division/drug effects/genetics
MH  - Chromosome Aberrations
MH  - Cisplatin/pharmacology
MH  - Clone Cells
MH  - Cytogenetics
MH  - Drug Resistance, Neoplasm
MH  - Fluorouracil/pharmacology
MH  - Humans
MH  - Inhibitory Concentration 50
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Mice, Nude
MH  - Neoplasm Transplantation
MH  - Prostatic Neoplasms/drug therapy/*genetics/*pathology
MH  - Tumor Cells, Cultured
EDAT- 2001/02/15 11:00
MHDA- 2001/03/27 10:01
CRDT- 2001/02/15 11:00
PHST- 2001/02/15 11:00 [pubmed]
PHST- 2001/03/27 10:01 [medline]
PHST- 2001/02/15 11:00 [entrez]
AID - S0165-4608(00)00332-0 [pii]
AID - 10.1016/s0165-4608(00)00332-0 [doi]
PST - ppublish
SO  - Cancer Genet Cytogenet. 2001 Jan 15;124(2):98-104. doi: 
      10.1016/s0165-4608(00)00332-0.